Special Issue

Autologous Stem Cell Transplantation

Submission Deadline: July 15, 2022 (Closed)

Guest Editor

Alessandra Picardi, PhD

Director, Division of Hematology and Stem Cell Transplantation Program, AORN Cardarelli Hospital, 80128 Naples, Italy;

Assistant Professor in Haematology at Biomedicine and Prevention Department, Tor Vergata University, Roma, Italy

Website | E-Mail

Research Interest: Stem cell transplantation; autologous stem cell transplantation; allogeneic haematopoietic stem cell transplantation; bone marrow transplantation; transplant immune; leukemia

Co-Editor

Nidhi Sharma, PhD

Internal Medicine, Division of Hematology, Ohio State University, Columbus, OH, USA

E-Mail

Research Interest: Graft vs host disease (GVHD); allogenic stem cell transplantation; autologous stem cell transplantation; stem cell transplantation

About This Topic

The number of autologous transplants recipients in the United States had steadily increased since 2000, rising up to 14.006 transplant procedures in 2018 (Blood and Marrow Research database). Autologous haemopoietic stem cell transplant (HSCT) still represents over 60% of transplant activity worldwide, although the new approved drugs and cellular therapies has slightly decreased the number of procedures for some haematological disease in the last 5 years. The most common indications for autologous HSCT remains multiple myeloma and lymphoma (Non Hodgkin and Hodgkin) in adult patients whereas its application is mainly related to solid tumors and refractory lymphomas in pediatric population.

The selection of optimal post-complete remission therapeutic strategy represents a crucial step for preventing relapse in most of haematological malignancies and the role of autologous HSCT, as valid alternative option, has been evaluated also in the setting of low risk Acute Leukemias. The low mortality rate allows its feasibility also in elderly patients with a trend to increased use up to 70-75 years.

Finally, autologous HSCT is the only treatment that is able to induce long-term, drug-free and symptom-free remission in several refractory autoimmune diseases, exploiting two main effects: 1) the immune system reset by renewing the CD4+ T cell compartment and 2) T cell receptor diversity and function restoring.

The scope of this volume will be to point out the main news about the conditioning regimens according to the underlying haematological or autoimmune disease,.in autologous HSCT.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (transplantation@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!

Publication

Open Access Original Research Organ System Bleeding in the PLADO Trial by Lynne Uhl  , Taye H. Hamza  , Terry Gernsheimer  and Sherrill J. Slichter Received: 30 December 2021;  Published: 26 April 2022;  doi: 10.21926/obm.transplant.2202158 Abstract In the multi-institutional platelet dose trial (PLADO Trial), there were 1,077 hematology/oncology patients ≥18 years of age who received at least one platelet transfusion. These patients were analyzed for types and severity of organ system bleeding based on baseline patient characteristics, laboratory assays, primary diagnosis, and type [...]

Open Access Case Report Efficacy of Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma in HIV-Positive Patients by Bin Ni  , Nidhi Sharma  , Ashley Rosko  , Don M. Benson  and Yvonne A. Efebera Received: 12 April 2021;  Published: 09 July 2021;  doi: 10.21926/obm.transplant.2103148 Abstract Prior to the advent of anti-retroviral therapy (ART), autologous stem cell transplant (ASCT) was relatively contraindicated for multiple myeloma (MM) patients with human immunodeficiency virus (HIV) due to issues associated with stem cell harvest and the risk of opportunistic infections. With the widespread use of ART for control [...]